Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2014 Aug 21;124(8):1216-7.
doi: 10.1182/blood-2014-06-579672.

FFS: an end(point) to our problems in chronic GVHD trials?

David A Jacobsohn  1
Affiliations
Comment

FFS: an end(point) to our problems in chronic GVHD trials?

David A Jacobsohn. Blood. .

Abstract

In this issue of Blood, Inamoto et al provide encouragement that we are reaching the time where we have a robust endpoint to use in large, randomized clinical trials testing novel agents in chronic graft-versus-host disease (GVHD).

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The author declares no competing financial interests.

Figures

None
FFS after initial systemic treatment of chronic GVHD. The dark gray area represents treatment failure due to recurrent malignancy. The light gray area represents treatment failure due to NRM, and the black area represents treatment failure due to treatment change. The white area represents FFS. The dashed line represents cumulative incidence of successful withdrawal of all systemic immunosuppressive treatment (IST) during initial treatment. See Figure 1 in the article by Inamoto et al that begins on page 1363.
See this image and copyright information in PMC

Comment on

References

    1. Inamoto Y, Flowers MED, Sandmaier BM, et al. Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. Blood. 2014;124(8):1363–1371. - PMC - PubMed
    1. Koc S, Leisenring W, Flowers ME, et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100(1):48–51. - PubMed
    1. Sullivan KM, Witherspoon RP, Storb R, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72(2):546–554. - PubMed
    1. Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009;113(21):5074–5082. - PMC - PubMed
    1. Gilman AL, Schultz KR, Goldman FD, et al. Randomized trial of hydroxychloroquine for newly diagnosed chronic graft-versus-host disease in children: a Children’s Oncology Group study. Biol Blood Marrow Transplant. 2012;18(1):84–91. - PMC - PubMed